Evofem Biosciences, Inc. (EVFM) Form 10-Q — May 15, 2026
Evofem Biosciences reported a net loss of $5.5 million for the three months ended March 31, 2026, driven by operating expenses of $5.5 million against product sales of $899,000. The company faces severe liquidity constraints, disclosing a working capital deficit of $72.7 million and total liabilities of $80.1 million against total assets of $7.4 million. Management explicitly stated that liquidity resources are insufficient to maintain cash flow needs for the next 12 months, raising substantial doubt about the company’s ability to continue as a going concern.
Key figures
- Revenue
- 899000
- Total Debt
- 169941000
- Total Assets
- 7442000
- Cash Position
- 1491000
- Shares Outstanding
- 132530081
- Reverse Split Ratio
- 1-for-500 to 1-for-1,500
- Baker Notes Fair Value
- 15181000
- Adjuvant Notes Balance
- 33384000
- Baker Notes Principal Plus Interest
- 123175000
Price after filing
Close on the filing date to close N calendar days later (from $0.01). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.